Predictors of Response to Intravitreal Bevacizumab in Diabetic Macular Edema: A Prospective Study in Tanzania
Journal of Ophthalmology of Eastern, Central and Southern Africa (JOECSA) · 01.08.2026 · 15 (02)
DOI: 10.64666/joecsa.2026.89 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ophthalmology of Eastern, Central and Southern Africa (JOECSA), online erschienen am 01.08.2026. Verfasst von Heavenlight Masuki und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To assess the clinical outcomes and predictors of response to intravitreal bevacizumab injections (IVB) in patients with diabetic macular edema (DME) at Muhimbili National Hospital (MNH). Methodology: A prospective longitudinal study was conducted at MNH for six months. Patients received monthly IVB (1.25 mg/0.05 mL) for three consecutive months. Baseline and post-treatment assessments included ocular examination, spectral-domain optical coherence tomography (OCT), and laboratory investigations. Main outcome measures were changes in best-corrected visual acuity (BCVA, logMAR) and central macular thickness (CMT, µm) at 12 weeks. Data were analyzed using SPSS v25 with paired t-test and linear regression, and p < 0.05 was considered statistically significant.
Results
Of the 60 patients, 58.3% were male, with a median age of 60.5 years (IQR 44). More than half (56.7%) had diabetes for 11–20 years, and 83.3% had HbA1c >7%. Baseline mean BCVA was 0.876 ± 0.592 logMAR, and mean CMT was 453.02 ± 71.94 µm. At 12 weeks, mean BCVA improved by 0.216 ± 0.523 logMAR (p = 0.002), equivalent to a >10-letter gain, and mean CMT decreased by 95.78 ± 57.65 µm (p < 0.001). Longer diabetes duration was significantly associated with less CMT reduction, with each additional year corresponding to a 0.434 µm increase in CMT (p = 0.003). Elevated HbA1c also predicted poor anatomical response, with each 1% increase associated with a 0.434 µm increase in CMT (p = 0.003).
Conclusion
Three intravitreal bevacizumab injections (IVB) resulted in a significant reduction in diabetic macular edema, marked by a decrease in central macular thickness and accompanied by a significant improvement in mean best-corrected visual acuity. Longer diabetes duration and poor glycemic control predict poor anatomical response, highlighting the importance of integrated diabetes management and structured treatment protocols in resource-limited settings.
Zitieren
APA
Masuki, H., & Haji, Z. (2026). Predictors of Response to Intravitreal Bevacizumab in Diabetic Macular Edema: A Prospective Study in Tanzania. Journal of Ophthalmology of Eastern, Central and Southern Africa (JOECSA), 15(02). https://doi.org/10.64666/joecsa.2026.89
Vancouver
Masuki H, Haji Z. Predictors of Response to Intravitreal Bevacizumab in Diabetic Macular Edema: A Prospective Study in Tanzania. Journal of Ophthalmology of Eastern, Central and Southern Africa (JOECSA). 2026;15(02). doi:10.64666/joecsa.2026.89
BibTeX
@article{Masuki2026,
author = {Masuki, Heavenlight and Haji, Zuleikha},
title = {Predictors of Response to Intravitreal Bevacizumab in Diabetic Macular Edema: A Prospective Study in Tanzania},
journal = {Journal of Ophthalmology of Eastern, Central and Southern Africa (JOECSA)},
year = {2026},
volume = {15},
number = {02},
doi = {10.64666/joecsa.2026.89}
}
EUVIMED